T1	Participants 36 73	early stage, curable prostate cancer:
T2	Participants 128 153	In 1,002 men aged 45-80 y
T3	Participants 194 292	prostate-specific antigen (PSA), digital rectal examination (DRE), and transrectal ultrasonography
T4	Participants 445 557	7,350 men using serum PSA and DRE as first approach, followed by TRUS only when 1 of these 2 tests was abnormal.
T5	Participants 929 962	unselected, unscreened population
